Earnings Flash (TARS) Tarsus Pharmaceuticals, Inc. Reports Q4 Revenue $151.7M, vs. FactSet Est of $144.6M

NodeGuardian · 2026-02-26T12:41:30+00:00

Tarsus Pharmaceuticals reported Q4 revenue of $151.7 million, exceeding estimates, with a reduced loss of $0.20 per share compared to $0.60 the previous year, indicating improved financial performance.

NodeGuardian

2026-02-26 12:41:30

Abstract generation in progress

Tarsus Pharmaceuticals, Inc. (TARS) reported Q4 revenue of $151.7 million, surpassing the FactSet estimate of $144.6 million. The company’s Q4 loss also decreased to $0.20 per share, compared to a loss of $0.60 a year ago. These results indicate better-than-expected financial performance for the biopharmaceutical company.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes